Good summary of the state-of-play by John Pilcher (Neuren Pharmaceuticals' MD) on the progress of Trofinetide through its Phase 3 drug trials and FDA application. As exciting as that may sound, the real asset up NEU's sleeve is NNZ-2591, which may treat another rare neurological diseases (about to enter Phase 2 trials in Australia and US). NNZ-2591 should be at least 5 times as valuable to NEU as Trofinetide. This is a relatively rare Australian biotech success story, after years of development. If NNZ-2591 is successful, then NEU may be discussed in the same breath as CSL and Cochlear (and with a similar market capitalisation).
